Loading…
Cian Healthcare (BSE 542678)₹37.68+4.00%Pharmaceuticals
In the Mar 2026 quarter (consolidated), Cian Healthcare reported sales of ₹17.04 Cr, up 41.6% from Mar 2025, and net profit of −₹18.02 Cr. For the year to Mar 2026, sales were ₹28.07 Cr and net profit −₹23.02 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 31.06 | 33.12 | 62.20 | 19.07 | 12.03 | 17.04 |
| Expenses | 23.99 | 27.99 | 50.99 | 20.01 | 16.99 | 19.99 |
| Operating Profit | 6.99 | 3.99 | 10.99 | −0.99 | −4.99 | −2.99 |
| OPM % | 22.1% | 14.1% | 18.1% | −7.9% | −44.0% | −17.9% |
| Other Income | 0.00 | 0.00 | 0.00 | −11.97 | 0.00 | −12.98 |
| Interest | 3.01 | 3.01 | 6.01 | 2.01 | 1.01 | 0.00 |
| Depreciation | 3.01 | 3.01 | 5.01 | 2.01 | 2.01 | 2.01 |
| Profit before tax | 2.01 | −1.01 | 0.00 | −18.03 | −8.01 | −18.01 |
| Tax % | 14.0% | 37.0% | −400.0% | 0.0% | 0.0% | 0.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | −12.04 | −0.19 | −13.26 |
| Net Profit | 2.01 | −1.01 | 0.00 | −18.02 | −8.01 | −18.02 |
| EPS (Rs) | 0.63 | −0.60 | 0.11 | −7.32 | −3.10 | −7.20 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 57.15 | 74.19 | 78.19 | 69.14 | 62.20 | 31.09 | 28.07 |
| Expenses | 49.95 | 61.98 | 74.03 | 55.99 | 50.99 | 36.99 | 34.98 |
| Operating Profit | 6.99 | 11.99 | 3.99 | 12.98 | 10.99 | −6.99 | −6.99 |
| OPM % | 13.1% | 16.1% | 6.0% | 19.1% | 18.1% | −21.0% | −23.9% |
| Other Income | 0.99 | 0.00 | 0.00 | 0.99 | 0.00 | −11.98 | −11.98 |
| Interest | 7.01 | 8.02 | 7.01 | 6.01 | 6.01 | 3.01 | 0.00 |
| Depreciation | 4.01 | 3.01 | 4.01 | 5.01 | 5.01 | 4.01 | 4.01 |
| Profit before tax | −4.01 | 1.01 | −6.01 | 2.01 | 0.00 | −26.02 | −23.02 |
| Tax % | 7.0% | 91.0% | −8.0% | −2.0% | −1,600.0% | 0.0% | 0.0% |
| Exceptional items | −0.05 | −0.01 | −0.06 | 0.08 | 0.00 | −12.23 | −13.22 |
| Net Profit | −4.01 | 0.00 | −6.01 | 2.01 | 1.01 | −26.04 | −23.02 |
| EPS (Rs) | −1.63 | 0.03 | −2.22 | 0.82 | 0.35 | −10.41 | −9.33 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 23.06 | 23.05 | 25.03 | 25.06 | 25.04 | 25.03 | 25.02 |
| Reserves | 35.09 | 35.06 | 30.04 | 32.07 | 33.05 | 7.01 | −15.94 |
| Borrowings | 73.15 | 71.09 | 63.05 | 61.12 | 56.08 | 55.03 | 28.99 |
| Other Liabilities | 25.12 | 28.14 | 47.22 | 42.21 | 47.23 | 69.33 | 24.11 |
| Total Liabilities | 157 | 157 | 166 | 160 | 161 | 156 | 62.18 |
| Fixed Assets | 39.17 | 37.15 | 50.16 | 45.20 | 39.15 | 35.12 | 32.13 |
| CWIP | 25.01 | 26.01 | 13.01 | 14.02 | 15.01 | 15.01 | 6.01 |
| Investments | 5.01 | 5.02 | 5.02 | 5.02 | 5.02 | 5.02 | 0.00 |
| Other Assets | 87.23 | 90.16 | 98.15 | 97.22 | 102 | 101 | 23.04 |
| Inventories | 19.67 | 30.64 | 39.30 | 36.58 | 40.86 | 26.01 | 5.04 |
| Trade receivables | 19.92 | 18.85 | 26.64 | 26.15 | 20.43 | 17.33 | 12.61 |
| Cash & equivalents | 3.46 | 2.33 | 1.35 | 1.34 | 1.20 | 17.81 | 1.21 |
| Total Assets | 157 | 157 | 166 | 160 | 161 | 156 | 62.18 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | −7.02 | 6.01 | 9.02 | 5.01 | 12.02 | 21.05 | 21.05 |
| Cash from investing activity | −26.92 | 2.99 | 0.99 | 2.99 | −0.99 | 0.00 | 12.97 |
| Cash from financing activity | 36.09 | −10.02 | −11.02 | −7.01 | −10.02 | −4.01 | −50.13 |
| Net cash flow | 1.01 | −1.01 | −1.01 | 0.00 | 0.00 | 17.07 | −17.05 |
| Capex | 0.97 | 0.57 | 17.37 | 0.45 | 0.18 | 0.05 | 0.83 |
| Free cash flow | −26.01 | 4.01 | 4.01 | 4.01 | 10.99 | 20.01 | 29.01 |
| CFO / OP % | −99.1% | 48.9% | 197.0% | 36.9% | 105.9% | −315.1% | −296.1% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 127 | 93 | 124 | 139 | 120 | 205 | 162 |
| Inventory days | 214 | 277 | 300 | 400 | 486 | 420 | 82 |
| Days payable | 176 | 186 | 270 | 296 | 371 | 671 | 219 |
| Cash conversion cycle | 166 | 185 | 155 | 244 | 236 | −45 | 26 |
| Working capital days | 15 | 16 | 38 | 41 | 26 | −729 | −96 |
| ROCE % | — | 7.0% | 0.0% | 7.0% | 5.0% | −11.1% | −16.1% |
For the Mar 2026 quarter, Cian Healthcare reported sales of ₹17.04 Cr, up 41.6% year on year and net profit of −₹18.02 Cr. The operating margin was −17.9%.
Cian Healthcare's sales for the year to Mar 2026 were ₹28.07 Cr.
Net profit for the year to Mar 2026 was −₹23.02 Cr. Earnings per share over the same trailing period were ₹−9.33.
Cian Healthcare reported borrowings of ₹28.99 Cr at Mar 2026, against cash and equivalents of ₹1.21 Cr.
Cash from operations was ₹21.05 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹29.01 Cr.